SFG
AXSM icon

Strive Financial Group’s Axsome Therapeutics AXSM Stock Holding History

Strive Financial Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.4K Sell
312
-25
-7% -$5.42K 0.03% 228
2026
Q1 		$57K Hold
337
– – 0.03% 209
2025
Q4 		$61.5K Buy
+337
New +$47K 0.03% 204

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Strive Financial Group's AXSM Position: Q2 2026 in Review

Strive Financial Group reduced its Axsome Therapeutics (AXSM) stake by 7.4% in Q2 2026, selling an estimated $5.42K and leaving 312 shares worth $76.4K. The position accounts for 0.03% of the portfolio, ranked #228.

Strive Financial Group first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 503 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Strive Financial Group held 312 shares of Axsome Therapeutics worth $76.4K as of Q2 2026.
  • Strive Financial Group sold 25 Axsome Therapeutics shares in Q2 2026, an estimated $5.42K.
  • Axsome Therapeutics made up 0.03% of Strive Financial Group's portfolio in Q2 2026, its #228 holding.
  • Strive Financial Group first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 503 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Strive Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.